Retroviral vector for the administration and expression of replicon RNA expressing heterologous nucleic acids
US11135283B2 · kind B2 · utility
4Cited by
30References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 9, 2016 |
| Grant date | Oct 5, 2021 |
| Priority date | — |
| Expiry date | Apr 27, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2740/15043
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates generally to gene delivery using a chimeric, retroviral-RNA replicon vector particle for increased expression of transgenes in a host cell. In particular, the chimeric vectors described herein can be used in any of a variety of settings including gene therapy and vaccine settings.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.